Detalhe da pesquisa
1.
Clinical Pharmacokinetics of the Androgen Receptor Inhibitor Darolutamide in Healthy Subjects and Patients with Hepatic or Renal Impairment.
Clin Pharmacokinet
; 61(4): 565-575, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34866168
2.
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors.
Cancer Discov
; 11(1): 80-91, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32988960
3.
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results.
Leukemia
; 34(11): 2903-2913, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32733012
4.
Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
Eur J Drug Metab Pharmacokinet
; 44(6): 747-759, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31571146
5.
First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity.
Eur J Cancer
; 109: 103-110, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30711772
6.
Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy.
Cancers (Basel)
; 11(12)2019 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31835495
7.
Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent.
J Med Chem
; 61(22): 9889-9907, 2018 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30346772
8.
Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent.
Invest New Drugs
; 22(3): 231-40, 2004 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-15122070